De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study.

Authors :: Tang K
Rajeh A
Shaw KS
Nguyen N
Wan G
Hashemi KB
Castillo RL
Kwatra SG
LeBoeuf NR
Ann Vleugels R
Semenov YR
Source :: The British journal of dermatology [Br J Dermatol] 2024 Aug 14; Vol. 191 (3), pp. 460-462.
Publication Year :: 2024
Abstract: Competing Interests: Conflicts of interest Y.R.S. is an advisory board member/consultant of and has received honoraria from Incyte Corporation, Castle Biosciences, Galderma, Sanofi and Pfizer outside of the submitted work.

Subjects :: Humans
Female
Male
Middle Aged
Aged
Autoimmune Diseases drug therapy
Autoimmune Diseases mortality
Adult
Cohort Studies
Programmed Cell Death 1 Receptor antagonists & inhibitors
Connective Tissue Diseases drug therapy
Connective Tissue Diseases mortality
Connective Tissue Diseases immunology
B7-H1 Antigen antagonists & inhibitors
Immune Checkpoint Inhibitors therapeutic use
Immune Checkpoint Inhibitors adverse effects

Full Text Access

Tools